| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
83,459 |
75,566 |
$10.26M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
89,678 |
79,498 |
$9.83M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
12,384 |
10,974 |
$3.36M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
7,346 |
6,451 |
$1.29M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
10,187 |
9,377 |
$1.10M |
| 80053 |
Comprehensive metabolic panel |
67,276 |
59,505 |
$1.02M |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,808 |
4,177 |
$888K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,304 |
3,728 |
$552K |
| 84484 |
|
27,458 |
20,363 |
$451K |
| 80320 |
|
3,728 |
2,962 |
$341K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
16,902 |
14,813 |
$324K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,095 |
3,482 |
$215K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,912 |
2,459 |
$170K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
453 |
418 |
$79K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
630 |
538 |
$70K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
59,837 |
53,112 |
$66K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,536 |
1,221 |
$66K |
| 29827 |
|
12 |
12 |
$62K |
| 83605 |
|
3,466 |
2,636 |
$41K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
271 |
118 |
$33K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
373 |
277 |
$32K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
133 |
130 |
$31K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
742 |
700 |
$30K |
| 85027 |
|
90,557 |
79,559 |
$27K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
38,319 |
33,506 |
$22K |
| 71045 |
Radiologic examination, chest; single view |
36,560 |
32,365 |
$21K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
244 |
206 |
$21K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
123 |
104 |
$20K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
100 |
92 |
$14K |
| 80076 |
|
886 |
806 |
$13K |
| 84703 |
|
21,049 |
18,767 |
$11K |
| 83690 |
|
28,841 |
25,544 |
$8K |
| 93880 |
|
66 |
63 |
$8K |
| G0378 |
Hospital observation service, per hour |
339 |
172 |
$8K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
696 |
606 |
$8K |
| A0425 |
Ground mileage, per statute mile |
279 |
228 |
$7K |
| G0383 |
Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
63 |
53 |
$7K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
155 |
125 |
$6K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
21,494 |
19,040 |
$5K |
| 87634 |
|
74 |
72 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
25,193 |
21,968 |
$4K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,523 |
2,388 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
29,470 |
25,664 |
$4K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
18 |
15 |
$4K |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
13 |
13 |
$3K |
| 70496 |
|
29 |
24 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
1,471 |
1,341 |
$3K |
| 81001 |
|
10,014 |
9,131 |
$3K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,250 |
1,220 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
17,853 |
15,888 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
428 |
388 |
$3K |
| 87430 |
|
1,719 |
1,573 |
$3K |
| 85379 |
|
330 |
300 |
$2K |
| 81025 |
|
3,683 |
3,395 |
$2K |
| 87081 |
|
1,115 |
1,002 |
$2K |
| 81003 |
|
7,906 |
7,312 |
$1K |
| 93975 |
|
12 |
12 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
805 |
689 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
28,047 |
15,139 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
4,950 |
4,410 |
$832.92 |
| 73610 |
|
31 |
26 |
$774.82 |
| J7050 |
Infusion, normal saline solution, 250 cc |
20,631 |
17,091 |
$745.72 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,312 |
1,142 |
$587.13 |
| 70498 |
|
13 |
12 |
$549.33 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
898 |
838 |
$464.00 |
| 83880 |
|
80 |
77 |
$365.64 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
1,297 |
1,200 |
$288.03 |
| 90715 |
|
15 |
14 |
$261.00 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
48 |
24 |
$193.79 |
| 83735 |
|
350 |
311 |
$109.81 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
790 |
724 |
$55.18 |
| 82077 |
|
4,500 |
4,101 |
$41.04 |
| 73130 |
|
14 |
12 |
$21.46 |
| 85610 |
|
2,121 |
1,894 |
$18.30 |
| 82805 |
|
28 |
27 |
$9.29 |
| J2060 |
Injection, lorazepam, 2 mg |
1,490 |
1,164 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
340 |
317 |
$0.00 |
| 85730 |
|
266 |
252 |
$0.00 |
| 82550 |
|
46 |
38 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
488 |
426 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
60 |
53 |
$0.00 |
| 86901 |
|
83 |
77 |
$0.00 |
| 64415 |
|
28 |
26 |
$0.00 |
| 70486 |
|
12 |
12 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
55 |
53 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
369 |
234 |
$0.00 |
| 87088 |
|
36 |
24 |
$0.00 |
| 29826 |
|
12 |
12 |
$0.00 |
| 81015 |
|
37 |
37 |
$0.00 |
| 96376 |
|
59 |
50 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
15 |
14 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
13 |
13 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
14 |
13 |
$0.00 |
| 86850 |
|
12 |
12 |
$0.00 |
| 86140 |
|
17 |
17 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
12 |
12 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,202 |
1,011 |
$0.00 |
| 82248 |
|
1,539 |
1,351 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,344 |
1,251 |
$0.00 |
| 87400 |
|
110 |
102 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
121 |
112 |
$0.00 |
| 86900 |
|
83 |
77 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
289 |
260 |
$0.00 |
| 74018 |
|
12 |
12 |
$0.00 |
| 29823 |
|
13 |
13 |
$0.00 |
| 73562 |
|
16 |
15 |
$0.00 |
| 73630 |
|
16 |
15 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
15 |
13 |
$0.00 |